Lord Mancroft

To ask Her Majesty’s Government whether plans to introduce a hepatitis C improvement framework have been abandoned and, if so, why.

To ask Her Majesty’s Government what plans they have to review their hepatitis C strategy in the light of other European countries' strategies for tackling hepatitis C.

To ask Her Majesty’s Government how many people diagnosed with hepatitis C are eligible for treatment under the National Institute for Health and Care Excellence guidance for new direct acting antiviral drugs.

To ask Her Majesty’s Government how many hepatitis C patients NHS England is planning to treat in 2016–17.

To ask Her Majesty’s Government for what reason NHS England intends to treat only a specified number of patients in 2016–17, as defined by recently published run rates for operational delivery networks services.

To ask Her Majesty’s Government what progress Operational Delivery Networks have made in establishing services for prisoners diagnosed with hepatitis C.

To ask Her Majesty’s Government what steps they are taking to develop prison health workers' understanding of the prevention, diagnosis and treatment of hepatitis C.

To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 4 January (HL4665) about access to hepatitis C treatment, how frequently NHS England will publish reports on the minimum data set and when the first set of data on...

To ask Her Majesty’s Government when the national framework for hepatitis C, due for release in spring 2015, will be published, and why it has been delayed.

To ask Her Majesty’s Government what steps they are taking to ensure that NHS England and Public Health England provide data demonstrating that there is equitable access to the new hepatitis C treatment.

To ask Her Majesty’s Government how they plan to measure the effectiveness of the implementation of the new medicines for hepatitis C treatment, and when they will publish those results.

To ask Her Majesty’s Government when NHS England's revised service specification for Hepatitis C networks is expected to be published.

To ask Her Majesty’s Government what processes are in place to ensure that people living with Hepatitis C will be able to access new National Institute for Health and Care Excellence approved treatments from 31 July 2015.

To ask Her Majesty’s Government whether the commitment in the Conservative Party manifesto to increase the use of new and cost-effective medicines applies to treatments approved by the National Institute for Health and Care Excellence for Hepatitis C.

To ask Her Majesty’s Government whether it is possible to amend the National Institute for Health and Care Excellence's process and methodology for technology appraisals midway through an appraisal.

To ask Her Majesty’s Government how many meetings they have held with NHS England and the National Institute for Health and Care Excellence to discuss the appraisal and future availability of Hepatitis C medicines; and whether minutes of such discussions ...

To ask Her Majesty’s Government when the Accelerated Access Review will publish its views on the potential assessment of affordability in relation to the appraisal of new medicines.

To ask Her Majesty’s Government what assessment they have made of the impact on patient health of the delay of the National Institute for Health and Care Excellence guidance for Sovaldi for the treatment of Hepatitis C.

To ask Her Majesty’s Government what consultation has taken place on NHS England's request to the National Institute for Health and Care Excellence to defer the implementation of its guidance on the use of sofosbuvir for patients with Hepatitis C.

To ask Her Majesty’s Government when they expect that new treatments for Hepatitis C with cure rates in excess of 90 per cent will be made available on the National Health Service.